Clinical Characteristics and Outcomes of Hyperphosphatemia in patients with CKD Stages 1 to 2
Kidney and Blood Pressure Research · 2024
DOI: 10.1159/000540115 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney and Blood Pressure Research, 2024. Verfasst von Chao Xie und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Hyperphosphatemia, Renal Insufficiency, Chronic. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
There was limited research on the epidemiology of hyperphosphatemia in early-stage chronic kidney disease (CKD) patients. We aimed to explore the clinical characteristics and prognostic value of hyperphosphatemia in patients with CKD stages 1-2.
Methods
We enrolled adult patients with CKD stages 1-2 from 24 regional central hospitals across China. Hyperphosphatemia was defined as a serum phosphate level exceeding 1.45 mmol/L. The study outcomes included all-cause and cardiovascular (CV) mortality. Cox proportional hazard models were used to investigate the association of hyperphosphatemia with all-cause and CV mortality.
Results
Among 99,266 patients with CKD stages 1-2 across China, the prevalence of hyperphosphatemia was 8.3%. The prevalence of hyperphosphatemia was increased with the level of urinary protein and was higher in younger and female patients. Among 63,121 patients with survival information, during a median of 5.2 years follow-up period, there were 436 (8.0%) and 4,695 (8.1%) deaths in those with and without hyperphosphatemia, respectively. After adjusting for potential confounders, compared with patients without hyperphosphatemia, patients with hyperphosphatemia was associated with a higher risk of all-cause mortality (HR, 1.28, 95% CI, 1.16-1.41). Although nearly 60.3% of hyperphosphatemia could be relieved without phosphate-lowering drug therapy among patients with CKD stages 1-2, transient hyperphosphatemia was also associated with an increased risk of all-cause mortality (P=0.048).
Conclusions
Hyperphosphatemia was not rare in patients with CKD stages 1-2 and was associated with an increased risk of mortality. Clinicians should closely monitor serum phosphorus levels in patients with CKD, even in those with normal kidney function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
- National Clinical Research Center for Kidney Disease, Guangzhou, China.
- State Key Laboratory of Organ Failure Research, Guangzhou, China.
- Guangdong Provincial Institute of Nephrology, Guangzhou, China.
- Guangdong Provincial Key Laboratory of Renal Failure Research, Guangzhou, China.
- Department of Nephrology, The First People's Hospital of Foshan, Foshan, China.
Zitieren
APA
Xie, C., Gao, Q., Liu, J., Su, L., Pang, M., Zhou, S., Kong, Y., Nie, S., Liang, M., & CRDS study Investigators (2024). Clinical Characteristics and Outcomes of Hyperphosphatemia in patients with CKD Stages 1 to 2. Kidney and Blood Pressure Research. https://doi.org/10.1159/000540115
Vancouver
Xie C, Gao Q, Liu J, Su L, Pang M, Zhou S, et al. Clinical Characteristics and Outcomes of Hyperphosphatemia in patients with CKD Stages 1 to 2. Kidney and Blood Pressure Research. 2024. doi:10.1159/000540115
BibTeX
@article{Xie2024,
author = {Xie, Chao and Gao, Qi and Liu, Jiao and Su, Licong and Pang, Mingzhen and Zhou, Shiyu and Kong, Yaozhong and Nie, Sheng and Liang, Min and CRDS study Investigators, CRDS study Investigators},
title = {Clinical Characteristics and Outcomes of Hyperphosphatemia in patients with CKD Stages 1 to 2},
journal = {Kidney and Blood Pressure Research},
year = {2024},
doi = {10.1159/000540115}
}
EUVIMED